Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Metabolism. 2023 Jun 28;146:155644. doi: 10.1016/j.metabol.2023.155644

Fig. 7. Intraperitoneal injection of YTK-2205 mitigates NAFLD in high fat diet fed mice.

Fig. 7.

(A) H & E staining (left panel) and TG levels (right panel, n = 8) of liver treated with YTK-2205 or vehicle. Scale bars, 50 μm. (B) WB of liver samples treated with YTK-2205 or vehicle. IHC staining of (C) p62 and (D) LC3 in liver treated with YTK-2205 or vehicle. Scale bars, 40 μm (upper row), 5 μm (lower row). (E) WB of liver samples treated with YTK-2205 (20 mg/kg) or vehicle, with or without chloroquine (100 mg/kg, 5 h). (F) IHC staining of F4/80 in liver treated with YTK-2205 or vehicle. Scale bars, 200 μm (upper row), 25 μm (lower row). (G) Relative mRNA levels of inflammatory cytokines in liver treated with YTK-2205 or vehicle (n = 8). Serum levels of (H) triglyceride, (I) total cholesterol, (J) non-esterified fatty acids (NEFA), and (K) alanine aminotransferase in mice treated with YTK-2205 or vehicle (n = 8). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not significant.